Patents Assigned to PLS-Design GmbH
-
Patent number: 11065330Abstract: The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation.Type: GrantFiled: March 10, 2015Date of Patent: July 20, 2021Assignee: PLS-Design GmbHInventors: Reinhard Bredehorst, Thomas Grunwald, Carsten Schmidt-Weber
-
Patent number: 10238735Abstract: The invention relates to a pharmaceutical composition made of one or more preparation and comprising a therapeutically effective dose of at least one recombinant human C3-derivative and at least one antigen für vaccination.Type: GrantFiled: June 14, 2013Date of Patent: March 26, 2019Assignees: PLS-DESIGN GMBH, KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN, HELMHOLTZ ZENTRUM MUNCHEN FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT GMBHInventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
-
Patent number: 9446121Abstract: The present invention relates to a recombinant polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to nucleic acid encoding the polypeptide, expression vectors, host cells and methods of preparing the polypeptide, as well as diagnostic and pharmaceutical uses thereof.Type: GrantFiled: March 13, 2009Date of Patent: September 20, 2016Assignee: PLS-DESIGN GMBHInventor: Thomas Grunwald
-
Patent number: 8802836Abstract: The invention relates to nucleic acids encoding a novel Vespula venom protease or fragments thereof, in particular the protease Ves v 4, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to the expression of such nucleic acids to produce a recombinant Vespula venom protease, or recombinant fragments thereof, or synthetic peptides thereof. Such a protease or fragments thereof or synthetic peptides thereof are useful for diagnosis of insect venom allergy and for therapeutic treatment of insect venom allergy.Type: GrantFiled: March 3, 2010Date of Patent: August 12, 2014Assignee: PLS-Design GmbHInventors: Henning Seismann, Ingke Braren, Thomas Grunwald
-
Publication number: 20140178474Abstract: The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicants: PLS-Design GmbH, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Klinikum rechts der Isar der Technischen Universitaet MuenchenInventors: Reinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
-
Publication number: 20140163200Abstract: The invention relates to a method for the sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with different nucleic acid molecule species comprising nucleic acid molecules with nucleotides, wherein the nucleic acid molecules partially comprise a nucleic acid sequence that is complementary to a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the hybrids, wherein thereafter the hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence, and wherein the hybrid sequence information is optionally translated into the complementary PNA sequenType: ApplicationFiled: November 7, 2013Publication date: June 12, 2014Applicants: PLS-Design GmbH, RiNA NETZWERK RNA-TECHNOLOGIEN GMBHInventors: Reinhard Bredehorst, Jom Glockler, Thomas Grunwald, Mark Matzas, Edzard Spillner
-
Patent number: 8119769Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3 derivatives that are capable of forming C3 convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3 convertases, thus escaping the physiological degradation mechanisms.Type: GrantFiled: April 23, 2009Date of Patent: February 21, 2012Assignee: PLS Design, GmbHInventors: Johanna Kölln, Edzard Spillner, Reinhard Bredehorst
-
Publication number: 20120009187Abstract: The invention relates to nucleic acids encoding a novel Vespula venom protease or fragments thereof, in particular the protease Ves v 4, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to the expression of such nucleic acids to produce a recombinant Vespula venom protease, or recombinant fragments thereof, or synthetic peptides thereof. Such a protease or fragments thereof or synthetic peptides thereof are useful for diagnosis of insect venom allergy and for therapeutic treatment of insect venom allergy.Type: ApplicationFiled: March 3, 2010Publication date: January 12, 2012Applicant: PLS-DESIGN GMBHInventors: Henning Seismann, Ingke Braren, Thomas Grunwald
-
Patent number: 7897153Abstract: The instant application inter alia relates to chimeric fusion constructs comprising the extracellular portion of human Fc?RI? and at least one avian constant immunoglobulin domain and the use thereof for in vitro diagnostic purposes.Type: GrantFiled: October 17, 2006Date of Patent: March 1, 2011Assignee: PLS-Design GmbHInventors: Ingke Braren, Reinhard Bredehorst, Thomas Grunwald
-
Patent number: 7888068Abstract: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen C (Api m 5). The invention further relates to expression vectors, host cells and polypeptides encoded by the nucleic acid, as well as diagnostic and pharmaceutical uses thereof.Type: GrantFiled: June 26, 2007Date of Patent: February 15, 2011Assignee: PLS-Design GmbHInventors: Simon Blank, Benjamin Bockisch, Thomas Grunwald
-
Patent number: 7846690Abstract: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to expression vectors, host cells and polypeptides encoded by the nucleic acid, as well as diagnostic and pharmaceutical uses thereof.Type: GrantFiled: December 13, 2005Date of Patent: December 7, 2010Assignee: PLS-Design GmbHInventor: Thomas Grunwald
-
Patent number: 7696323Abstract: This invention relates to the field of recombinant antibody technology. It provides novel recombinant IgY antibody constructs for diagnostic and therapeutical applications. The bivalent antibody constructs display a heterotetrameric or homodimeric format stabilized by disulfide bonds. The constant heavy chain domains CH2-CH4 are partly or completely of avian origin, whereas the VH, VL, CL, and CH1 domains as well as the hinge region may be of avian origin or derived from any other species. The invention allows to combine the advantages of IgY antibodies with those of established mammalian monoclonal antibodies. IgY antibody constructs comprising nonglycosylated IgY constant heavy chain domains allow to reduce unwanted interactions with C-type lectins, e.g., in human sera.Type: GrantFiled: August 25, 2006Date of Patent: April 13, 2010Assignee: PLS-Design GmbHInventors: Reinhard Bredehorst, Kerstin Greunke, Thomas Grunwald, Edzard Spillner
-
Publication number: 20100081801Abstract: The invention relates to a method for determining an unknown PNA sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with one or several different nucleic acid molecule species comprising nucleic acid molecules with at least one nucleotide, wherein the nucleic acid molecules at least partially comprise a nucleic acid sequence that is complementary to at least a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the nucleic acid/PNA hybrids, wherein thereafter the nucleic acid/PNA hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence,Type: ApplicationFiled: October 17, 2006Publication date: April 1, 2010Applicants: RiNA Netzwerk RNA-Technologien GmbH, PLS-Design GmbHInventors: Reinhard Bredehorst, Jorn Glokler, Thomas Grunwald, Mark Matzas, Edzard Spillner
-
Publication number: 20100015122Abstract: The present invention relates to a recombinant polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to nucleic acid encoding the polypeptide, expression vectors, host cells and methods of preparing the polypeptide, as well as diagnostic and pharmaceutical uses thereof.Type: ApplicationFiled: March 13, 2009Publication date: January 21, 2010Applicant: PLS-DESIGN GMBHInventor: Thomas Grunwald
-
Patent number: 7553931Abstract: The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3-derivatives that are capable of forming C3-convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3-convertases, thus escaping the physiological degradation mechanisms.Type: GrantFiled: July 2, 2004Date of Patent: June 30, 2009Assignee: PLS-Design GmbHInventors: Johanna Kölln, Edzard Spillner, Reinhard Bredehorst
-
Publication number: 20080317669Abstract: The present invention relates to a nucleic acid encoding a polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen C (Api m 5). The invention further relates to expression vectors, host cells and polypeptides encoded by the nucleic acid, as well as diagnostic and pharmaceutical uses thereof.Type: ApplicationFiled: June 26, 2007Publication date: December 25, 2008Applicant: PLS-Design GmbHInventors: Simon Blank, Benjamin Bockisch, Thomas Grunwald